| 2 | Redox and structural determinants of mitochondrial complex III inhibition by triphenylphosphonium-conjugated atovaquone analogs. (Pereira Resende BR, Cheng G, Canard G, Siri D, Leone V, Hardy M, Kalyanaraman B) Redox Biol 2026 Nov;97:104370 1 Citation |
| 2 | Mitochondria-targeted agents disrupt bioenergetics in parasitic nematodes. (Cheng G, Hardy M, Kron MA, Kalyanaraman B) Arch Biochem Biophys 2026 Sep;783:110907 |
| 1 | Mitochondria-targeted atovaquone promotes anti-lung cancer immunity by reshaping tumor microenvironment and enhancing energy metabolism of anti-tumor immune cells. (Xiong D, Yin Z, Huang M, Wang Y, Hardy M, Kalyanaraman B, Wong ST, You M) Cancer Commun (Lond) 2024 Mar;44(3):448-452 20 Citations |
| 2 | Combining PEGylated mito-atovaquone with MCT and Krebs cycle redox inhibitors as a potential strategy to abrogate tumor cell proliferation. (Cheng G, Hardy M, You M, Kalyanaraman B) Sci Rep 2022 Mar 24;12(1):5143 17 Citations |
| 1 | Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria-Targeted Atovaquone. (Huang M, Xiong D, Pan J, Zhang Q, Wang Y, Myers CR, Johnson BD, Hardy M, Kalyanaraman B, You M) Adv Sci (Weinh) 2022 Apr;9(12):e2101267 46 Citations |
| 1 | Exploiting the tumor immune microenvironment and immunometabolism using mitochondria-targeted drugs: Challenges and opportunities in racial disparity and cancer outcome research. (Kalyanaraman B) FASEB J 2022 Apr;36(4):e22226 22 Citations |
| 2 | Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone. (Cheng G, Hardy M, Topchyan P, Zander R, Volberding P, Cui W, Kalyanaraman B) Sci Rep 2020 Oct 21;10(1):17872 46 Citations |
| 1 | Liver transplant, toxoplasmosis and kidney stones: connecting the dots. (Bejjanki H, Olaoye OA, Santos AH, Koratala A) BMJ Case Rep 2019 Feb 15;12(2) 2 Citations |
| 1 | 79-year-old man with fever, malaise, and jaundice. (Kreuziger LM, Tafur AJ, Thompson RL) Mayo Clin Proc 2009 Mar;84(3):281-4 1 Citation |